Frequently Asked Questions

The difference is that Tinearity G1 is a small device employing bone conduction technology. This means that the white or pink noise is introduced into the ear via the skull. This means that the ear canal is left unobstructed and that treatment and relief can be administered at work, at leisure, or while asleep.

When undergoing TRT treatment, we recommend that symptoms are treated with white noise 6–8 hours per day for 6–24 months.

When undergoing TRT treatment, we recommend that symptoms are treated with white noise for 6–8 hours per day. The battery charge lasts at least 8 hours, after which time the device need to be recharged.

You can use Tinearity G1 for a least 8 hours per day before you need to recharge the batteries. The sound generating device rests behind the ear and is charged by placing it on a charging plate included when you buy Tinearity G1. The battery life lasts more than two years.

The patch holding the device in place behind the ear is medical technology-classified and dermatologically tested. It cannot be ruled out that it may induce rashes or some form of discomfort for some people.

No. Tinearity G1 can be used within the framework of TRT treatment and for self-relief.

No, the devices emitting white noise through the skull bone are affixed with a small patch on the skin behind the ear.

Yes, the devices placed on the skin behind the ears are small, and tests show that it is possible to sleep with them on.

Yes, the devices emitting white noise are small and are placed on the skin behind the ear. This means that the ear canal is left unobstructed, making it possible to talk on the telephone or have a conversation with colleagues, and to take part meetings while simultaneously using Tinearity G1.

There is a series of various studies showing that white noise can help to alleviate the symptoms.

Tinearity G1 will be CE labelled as medical technology Class IIa. This means that Tinearity G1 will have undergone a series of tests, as well as being examined by an independent organisation (a 'Notified Body'). To CE-label a medicinal product means that it must live up to stringent requirements in accordance with the MDR directive.

All documentation from the development of Tinearity G1 will be sent to the Swedish Medical Products Agency for review. Once the product is ready and launched, the Swedish Medical Products Agency may review Tinearity G1, our marketing and the company behind the product at any time.